JPMorgan lowered the firm’s price target on Conmed (CNMD) to $52 from $58 and keeps a Neutral rating on the shares. The company reported a good Q3 amid “slow and steady” supply and execution improvements, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD: